These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
607 related articles for article (PubMed ID: 12613177)
1. NMR-based screening methods for lead discovery. Vogtherr M; Fiebig K EXS; 2003; (93):183-202. PubMed ID: 12613177 [TBL] [Abstract][Full Text] [Related]
2. NMR fragment screening: Advantages and applications. Schade M IDrugs; 2006 Feb; 9(2):110-3. PubMed ID: 16523400 [TBL] [Abstract][Full Text] [Related]
3. Protein-ligand NOE matching: a high-throughput method for binding pose evaluation that does not require protein NMR resonance assignments. Constantine KL; Davis ME; Metzler WJ; Mueller L; Claus BL J Am Chem Soc; 2006 Jun; 128(22):7252-63. PubMed ID: 16734479 [TBL] [Abstract][Full Text] [Related]
4. Technological advances in high-throughput screening. Liu B; Li S; Hu J Am J Pharmacogenomics; 2004; 4(4):263-76. PubMed ID: 15287820 [TBL] [Abstract][Full Text] [Related]
5. High-throughput nuclear magnetic resonance-based screening. Hajduk PJ; Gerfin T; Boehlen JM; Häberli M; Marek D; Fesik SW J Med Chem; 1999 Jul; 42(13):2315-7. PubMed ID: 10395471 [TBL] [Abstract][Full Text] [Related]
6. Library design for fragment based screening. Schuffenhauer A; Ruedisser S; Marzinzik AL; Jahnke W; Blommers M; Selzer P; Jacoby E Curr Top Med Chem; 2005; 5(8):751-62. PubMed ID: 16101415 [TBL] [Abstract][Full Text] [Related]
7. Integration of NMR and high-throughput screening. Hajduk PJ; Burns DJ Comb Chem High Throughput Screen; 2002 Dec; 5(8):613-21. PubMed ID: 12470258 [TBL] [Abstract][Full Text] [Related]
8. Advancing fragment binders to lead-like compounds using ligand and protein-based NMR spectroscopy. Maurer T Methods Enzymol; 2011; 493():469-85. PubMed ID: 21371602 [TBL] [Abstract][Full Text] [Related]
9. The SHAPES strategy: an NMR-based approach for lead generation in drug discovery. Fejzo J; Lepre CA; Peng JW; Bemis GW; Ajay ; Murcko MA; Moore JM Chem Biol; 1999 Oct; 6(10):755-69. PubMed ID: 10508679 [TBL] [Abstract][Full Text] [Related]
11. Application of NMR and molecular docking in structure-based drug discovery. Stark JL; Powers R Top Curr Chem; 2012; 326():1-34. PubMed ID: 21915777 [TBL] [Abstract][Full Text] [Related]
12. Applications of NMR screening techniques to the pharmaceutical target Checkpoint kinase 1. Lancelot N; Piotto M; Theret I; Lesur B; Hennig P J Pharm Biomed Anal; 2014 May; 93():125-35. PubMed ID: 24280017 [TBL] [Abstract][Full Text] [Related]
13. MS/NMR: a structure-based approach for discovering protein ligands and for drug design by coupling size exclusion chromatography, mass spectrometry, and nuclear magnetic resonance spectroscopy. Moy FJ; Haraki K; Mobilio D; Walker G; Powers R; Tabei K; Tong H; Siegel MM Anal Chem; 2001 Feb; 73(3):571-81. PubMed ID: 11217765 [TBL] [Abstract][Full Text] [Related]
14. A general technique to rank protein-ligand binding affinities and determine allosteric versus direct binding site competition in compound mixtures. Annis DA; Nazef N; Chuang CC; Scott MP; Nash HM J Am Chem Soc; 2004 Dec; 126(47):15495-503. PubMed ID: 15563178 [TBL] [Abstract][Full Text] [Related]
15. Combining in silico tools and NMR data to validate protein-ligand structural models: application to matrix metalloproteinases. Bertini I; Fragai M; Giachetti A; Luchinat C; Maletta M; Parigi G; Yeo KJ J Med Chem; 2005 Dec; 48(24):7544-59. PubMed ID: 16302796 [TBL] [Abstract][Full Text] [Related]